Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.9
5.2
Journals
Vaccines
Special Issues
Advances in Human Monkeypox Vaccines Effectiveness, Safety and Hesitancy
share announcement

Advances in Human Monkeypox Vaccines Effectiveness, Safety and Hesitancy

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines against Infectious Diseases".

Deadline for manuscript submissions: 20 October 2024 | Viewed by 7006

Special Issue Editor

Dr. Abanoub Riad

E-Mail Website
Guest Editor
1. Department of Public Health, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
2. Institute of Health Information and Statistics of the Czech Republic (IHIS-CR), 128 01 Prague, Czech Republic
3. Czech National Center of Evidence-based Healthcare and Knowledge Translation (Cochrane Czech Republic, Czech EBHC: JBI Centre of Excellence, Masaryk University GRADE Centre), Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
Interests: global health; clinical epidemiology; infectious diseases; health psychology; dental public health
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The human monkeypox (HMPX) outbreak of 2022 did not only cause several thousands of cases in non-endemic countries but also triggered multi-faceted debates about epidemic preparedness, discontinuation of smallpox vaccination, effectiveness and safety of the repurposed smallpox vaccines and drugs, and public interest in (acceptance of) immunization against orthopoxviruses.

I am pleased to invite you to participate in this Special Issue which aims to delve into three main thematic areas around HMPX vaccination.

Firstly, the effectiveness of the repurposed smallpox vaccines that are used as pre- or post-exposure prophylaxis needs to be evaluated within the context of the ongoing outbreak, especially among high-risk groups and healthcare settings.

Secondly, pre- and post-authorization safety of HMPX vaccines and antivirals should be actively monitored in order to update the current immunization guidelines in light of the best available evidence.

Thirdly, vaccination acceptance and misconceptions among healthcare professionals, students, and high-risk groups are of utmost importance amid this outbreak because they may either accelerate or unnecessarily delay the task of epidemic control.

I look forward to receiving your contributions.

Dr. Abanoub Riad
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • orthopoxviruses
  • monkeypox virus
  • smallpox vaccine
  • vaccination hesitancy
  • vaccine effectiveness
  • drug-related side effects and adverse reactions
  • adverse drug reaction reporting systems
  • health belief model
  • theory of planned behavior
  • infodemic

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

15 pages, 955 KiB  
Article
Perception of and Vaccine Readiness towards Mpox among Men Who Have Sex with Men Living with HIV in China: A Cross-Sectional Study
by Leiwen Fu, Yinghui Sun, Yuwei Li, Bingyi Wang, Luoyao Yang, Tian Tian, Xinsheng Wu, Xin Peng, Qi Liu, Yuanyi Chen, Yi-Fan Lin, Hui Li, Xiaojun Meng and Huachun Zou
Vaccines 2023, 11(3), 528; https://doi.org/10.3390/vaccines11030528 - 23 Feb 2023
Cited by 14 | Viewed by 2512
Abstract
Background: Men who have sex with men (MSM) living with HIV make up the majority of cases in the current Mpox outbreak. We aimed to investigate the perception of and vaccine readiness towards Mpox among MSM living with HIV in China. Methods: This [...] Read more.
Background: Men who have sex with men (MSM) living with HIV make up the majority of cases in the current Mpox outbreak. We aimed to investigate the perception of and vaccine readiness towards Mpox among MSM living with HIV in China. Methods: This cross-sectional online study was conducted from 10 August to 9 September 2022. Participants responded to survey questions about their socio-demographic information, HIV status, sexual behaviors, knowledge of Mpox, and attitudes towards Mpox vaccines. Results: A total of 577 MSM living with HIV participated in the study. A total of 37.6% expressed concerns about the Mpox epidemic in China, and 56.8% were willing to get the Mpox vaccine. Men who had > four sexual partners in the previous three months (aOR = 1.9 95% CI: 1.2–2.8 Ref: 0), had close contact with > four individuals in a day (3.1, 1.5–6.5 Ref: 0–3), were worried about the Mpox epidemic in China (1.6, 1.1–2.3 Ref: No), and believed that Mpox vaccines are safe (6.6, 2.7–16.4 Ref: No or not sure) and effective (1.9, 1.1–3.3 Ref: No) for people living with HIV were more likely to be willing to get the Mpox vaccine. MSM living with HIV with a high school education or below (0.5, 0.3–0.9 Ref: Postgraduate diploma), and sometimes (0.5, 0.3–0.8 Ref: Often), seldom, or never (0.5, 0.3–0.9 Ref: Often) followed news about Mpox were unwilling to get the Mpox vaccine. Conclusion: The ongoing Mpox pandemic has not attracted widespread concerns among MSM living with HIV in China. Having more sexual partners and close contacts, worrying about the Mpox epidemic, and believing in the vaccine’s safety and efficacy were predictors of their willingness to get the Mpox vaccine. Efforts should be made to raise awareness of the potential risk of Mpox in this at-risk population. Public health strategies should fully address predictors of vaccination willingness. Full article
(This article belongs to the Special Issue Advances in Human Monkeypox Vaccines Effectiveness, Safety and Hesitancy)
►▼ Show Figures

Figure 1

Review

Jump to: Research, Other

11 pages, 3986 KiB  
Review
Monkeypox (MPOX)-Related Knowledge and Vaccination Hesitancy in Non-Endemic Countries: Concise Literature Review
by Mohamed Lounis and Abanoub Riad
Vaccines 2023, 11(2), 229; https://doi.org/10.3390/vaccines11020229 - 19 Jan 2023
Cited by 20 | Viewed by 2603
Abstract
In May 2022, the world witnessed the emergence of human monkeypox (MPOX), a new zoonotic viral disease in multiple non-endemic countries. This health threat has been associated with increased anxiety, especially after the COVID-19 catastrophe. In addition, people are exposed to an unprecedented [...] Read more.
In May 2022, the world witnessed the emergence of human monkeypox (MPOX), a new zoonotic viral disease in multiple non-endemic countries. This health threat has been associated with increased anxiety, especially after the COVID-19 catastrophe. In addition, people are exposed to an unprecedented amount of information, making them vulnerable to misinformation that may lead to embracing conspiracy theories. This literature review was conducted to evaluate the levels of MPOX-related knowledge and attitudes toward its vaccination by reviewing studies indexed in MEDLINE® until 15 November 2022. A total of 16 studies conducted in non-endemic countries were included in this review, predominantly in Europe, the Middle East, and Asia. Nine studies investigated exclusively MPOX-related knowledge and awareness, and two studies were exclusively related to MPOX vaccines, while five studies dealt with both topics. The target populations were mainly healthcare professionals and the general adult population. The results revealed an unsatisfactory level of knowledge and awareness among certain groups. Regarding vaccination, the results showed that vaccine hesitancy is still common for healthcare professionals except among Chinese healthcare professionals, where the rate of vaccine acceptance was estimated at 90.1%. This review could help understand the MPOX-related knowledge and awareness and vaccine hesitancy in the first months of the emergence of the MPOX by comparing their evolution in recent studies. Full article
(This article belongs to the Special Issue Advances in Human Monkeypox Vaccines Effectiveness, Safety and Hesitancy)
►▼ Show Figures

Figure 1

Other

Jump to: Research, Review

9 pages, 868 KiB  
Case Report
Simultaneous Multiple-Stages Mpox Genital Lesions on the Same Site in a Traveler to Greece: A Case Report
by Anna Tagka, Styliani Geronikolou, Apostolos Evaggelopoulos, Sotiria Grigoropoulou, Dimitra Kavatha, Chryssoula Botsi, Aggeliki Papadopoulou, Kyriaki Tryfinopoulou, Antigoni Katsoulidou, Styliani Pappa, Anna Papa, Vasilios Paparizos, Electra Nicolaidou, Sotirios Tsiodras and Alexandros J. Stratigos
Vaccines 2023, 11(5), 901; https://doi.org/10.3390/vaccines11050901 - 26 Apr 2023
Viewed by 1324
Abstract
A 47-year-old Caucasian traveller from an mpox (formerly monkeypox and also best suited abbreviated MPX)-endemic country was referred for a skin rash, of recent onset, confined to the genital area. The rash consisted of erythematous umbilicated papules, vesicles and pustules with a characteristic [...] Read more.
A 47-year-old Caucasian traveller from an mpox (formerly monkeypox and also best suited abbreviated MPX)-endemic country was referred for a skin rash, of recent onset, confined to the genital area. The rash consisted of erythematous umbilicated papules, vesicles and pustules with a characteristic white ring. The lesions were observed simultaneously at different stages of progression on the same anatomical site, a clinical presentation that is not encountered frequently. The patient was febrile, fatigued and had blood-tinged cough. The clinical suspicion of mpox was raised, and the initial real-time PCR identified a non-variola orthopox virus, which was confirmed at the National Reference Laboratory to belong to the West African clade. Full article
(This article belongs to the Special Issue Advances in Human Monkeypox Vaccines Effectiveness, Safety and Hesitancy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop